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PURPOSE. To evaluate relationships among retinal vascular caliber and biomarkers of systemic
inflammation in patients with AIDS.
METHODS. A total of 454 participants with AIDS had retinal vascular caliber (central retinal
artery equivalent and central retinal vein equivalent) determined from enrollment retinal
photographs by reading center graders masked to clinical and biomarker information.
Cryopreserved plasma specimens were assayed for inflammatory biomarkers, including C-
reactive protein (CRP), IL-6, interferon-c inducible protein (IP)-10, kynurenine/tryptophan
(KT) ratio, and intestinal fatty acid binding protein (I-FABP).
RESULTS. In the simple linear regression of retinal vascular caliber on plasma biomarkers,
elevated CRP, IL-6, and IP-10 were associated with retinal venular dilation, and elevated KT
ratio with retinal arteriolar narrowing. In the multiple linear regression, including baseline
characteristics and plasma biomarkers, AMD was associated with dilation of retinal arterioles
(mean difference: 9.1 lm; 95% confidence interval [CI] 5.2, 12.9; P < 0.001) and venules
(mean difference, 10.9 lm; 95% CI, 5.3, 16.6; P < 0.001), as was black race (P < 0.001).
Hyperlipidemia was associated with retinal venular narrowing (mean difference, 7.5 lm;
95% CI, 13.7, 1.2; P ¼ 0.02); cardiovascular disease with arteriolar narrowing (mean
difference, 5.2 lm; 95% CI, 10.3, 0.1; P ¼ 0.05); age with arteriolar narrowing (slope,
0.26 lm/year; 95% CI, 0.46, 0.06; P ¼ 0.009); and IL-6 with venular dilation (slope, 5.3
lm/standard deviation log10[plasma IL-6 concentration]; 95% CI, 2.7, 8.0; P < 0.001).
CONCLUSIONS. These data suggest that retinal vascular caliber is associated with age, race, AMD,
hyperlipidemia, cardiovascular disease, and selected biomarkers of systemic inflammation.
Keywords: retinal vascular caliber, inflammation, AIDS
Human immunodeficiency virus (HIV)-infected personstreated with modern antiretroviral therapy (ART) have
suppressed HIV replication, reduced amounts of HIV RNA
circulating in the blood (HIV viral load), improved immune
function typically manifested as a rise in CD4þT cells (immune
recovery), decreased opportunistic infections, and an improved
lifespan.1–4 Nevertheless, they have a shortened lifespan
compared to comparably aged HIV-uninfected persons, largely
due to age-related diseases.5,6 They have an increase is age-
related diseases such as cardiovascular disease, metabolic
disorders (e.g., diabetes and osteoporosis), neurocognitive
decline, and age-related cancers not associated with AIDS,7–10
suggesting accentuated and accelerated aging.9,10 They also
exhibit features of immunosenescence, a state characterized by
chronic immune activation and systemic inflammation, but a
poor response to new antigenic challenges.9–12 Compared to
HIV-uninfected persons, those with HIV infection have
persistently high levels of immune activation and systemic
inflammation, despite ART-mediated viral suppression, particu-
larly those who initiate ART at advanced stages of HIV
disease.13–15
Consistent with this accentuated/accelerated aging, persons
with AIDS have an ~4-fold increased age- and sex-adjusted
prevalence of intermediate-stage AMD compared to HIV-
uninfected persons16 and a ~1.75-fold increased race/ethnicity-
and sex-adjusted incidence of intermediate-stage AMD com-
pared to HIV-uninfected persons.17 Retinal vascular caliber
declines with age, and persons with AIDS have retinal arteriolar
and venular calibers comparable to HIV-uninfected persons
~10 years older.18 Although a decline in retinal vascular caliber
is associated with increasing age, persons with AIDS and AMD
have dilated retinal arterioles and venules compared to persons
with AIDS without AMD.19 Retinal venular dilation is associated
with systemic inflammation in HIV-uninfected persons.20–24
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Elevated blood levels of C-reactive protein (CRP) a biomarker
of systemic inflammation, are a risk factor for the development
of AMD in HIV-uninfected persons,25 and persons with AMD
have elevated blood levels of several proinflammatory cyto-
kines,26 suggesting that systemic inflammation might be a
common pathogenetic factor in both processes. Therefore, we
evaluated the relationship between several biomarkers of
systemic inflammation and retinal vascular caliber in persons
with AIDS enrolled in the Longitudinal Study of the Ocular
Complications of AIDS (LSOCA).
PATIENTS AND METHODS
The Longitudinal Study of the Complications of AIDS was a
prospective cohort study of patients with the acquired
immunodeficiency syndrome conducted in the era of modern
ART.27 Baseline photographs were taken on all participants and
evaluated for retinal vascular caliber at the Reading Center in
the Department of Ophthalmology and Visual Sciences at the
University of Wisconsin, Madison, School of Medicine and
Public Health by graders masked as to clinical data, as
previously described.18,19,28 As part of a study of AMD,
mortality, and biomarkers of systemic inflammation, partici-
pants with AMD at enrollment were matched on decade of age,
race/ethnicity-, and sex with 2 controls from LSOCA for a case
control study,29 resulting in a study population of 454 persons
with AIDS. Retinal vascular indices were determined using
previously-described semi-automated methods. Briefly, the six
largest arterioles and six largest venules in a ring-shaped area
located between 0.5 and 1.0 disc diameters from the edge of
the optic nerve were identified. Computer software measured
the caliber of the individual vessels, then combined them into
two summary measures: the central retinal artery equivalent
(CRAE) and central retinal vein equivalent (CRVE).18,19,28
Intermediate-stage AMD was graded at the reading center as
previously described.16,17,19,29
Phlebotomy was performed at enrollment, and plasma
specimens cryopreserved. Cryopreserved specimens were
thawed and assayed for biomarkers of inflammation using
commercially available immunoassay kits in the Core Immu-
nology Laboratories of the University of California, San
Francisco, School of Medicine as previously described.29,30
Inflammatory biomarkers included high-sensitivity CRP (UBI
Magiwel, Mountain View, CA, USA), IL-6 (hsIL-6, R&D Systems,
Minneapolis, MN, USA), soluble CD14 (sCD14, R&D Systems),
soluble CD163 (sCD163, R&D Systems), and interferon-c
inducible protein (IP)-10 (IP-10, R&D Systems), also known
as CXCL10. Intestinal fatty acid binding protein (I-FABP), a
marker of impaired gut epithelial integrity (R&D Systems), and
plasma kynurenine to tryptophan (KT) ratio, a marker of
dendritic cell indoleamine 2,3 dioxygenase (IDO) upregu-
lation,31 also were assessed. The kynurenine tryptophan (KT)
ratio was assayed using liquid chromatography-tandem mass
spectrometry.32
Statistics
Plasma inflammatory biomarker values were log10 transformed
for normality. In order to compare different biomarkers with
different dynamic ranges, results were standardized to the
standard deviation (SD) units of the log10(biomarker plasma
level). Testing of the direct association between inflammatory
biomarkers and retinal vascular caliber was performed using
simple linear regression and the independent association was
tested using multiple linear regression with forward selection
using a P value for entry 0.05 from a candidate set of 18
variables including the seven plasma biomarkers, AMD status,
hyperlipidemia, hypertension, diabetes, cardiovascular disease,
elevated creatinine, HIV load, CD4þ T-cell count, CD8þ T-cell
count, current use and any prior use of ART. Age, race/
ethnicity, and sex were forced into the model. Similar results
were obtained using backward selection and Bayesian Infor-
mation Criteria (data not shown). Mean central retinal artery
equivalent (CRAE) and central retinal vein equivalent (CRVE)
were tested across categoric variables at enrollment using
ANOVA. Results for categorical variables are expressed as the
mean difference in vascular CRAE or CRVE, whereas results for
continuous variable are expressed as the slope and 95%
confidence interval (CI) of the regression line for CRAE or
CRVE (in lm) per standardized unit of the biomarker. P values
were nominal and not adjusted for multiple outcomes or
multiple looks. The data analyses were generated using
statistical software (SAS version 9.4, SAS Institute Inc., Cary,
NC, and StataCorp, Release 15; StataCorp LLC, College Station,
TX, USA).
RESULTS
Characteristics of the study population are outlined in Table 1.
The relationships between baseline demographic, comorbid
disease, HIV treatment, HIV virologic, and immunologic
variables and retinal vascular caliber are outlined in Table 2.
Age-related macular degeneration was associated with retinal
arteriolar and venular dilation. Older age, male sex, white race,
hypertension, cardiovascular disease, receiving ART at enroll-
ment, and elevated HIV load all were associated with retinal
arteriolar narrowing. Female sex and black race were
associated with retinal venular dilation, whereas hyperlipid-
emia and receiving ART at enrollment were associated with
narrower retinal venules. There were no differences in age by
race/ethnicity (mean age: white 47.8 years, black 47.8 years,
other 46.8 [P¼0.70 by ANOVA]). There was a difference in the
frequency of hypertension by race/ethnicity (proportion with
hypertension: white, 23%; black, 30%; other 15% [P¼ 0.03 by
Fisher’s exact test]). Although there was a sex difference by
race/ethnicity (proportion women: white, 7%; black, 36%;
other, 27% [P < 0.001]), the frequency of hypertension did not
differ by sex (men, 24%; women, 25%). Overall the rate of
hypertension did not vary significantly by race/ethnicity and
sex (interaction P value¼ 0.26). Results of linear regression of
CRAE and CRVE versus inflammatory biomarker levels are
outlined in Table 3 and Figures 1 and 2. Venous dilation was
significantly associated with the biomarkers CRP, IL-6, and IP-
10. The corresponding slopes (95% CI) of CRVE versus plasma
biomarker in lm/standard deviation log10(plasma biomarker
concentration) and P values were: CRP¼ 3.7 (95 CI¼1.4, 6.0),
P¼ 0.002; IL-6¼ 3.7 (95% CI¼ 1.6, 5.8), P¼ 0.001; and IP-10¼
2.8 (95% CI¼ 0.6, 5.0), P¼ 0.01. Conversely, sCD14, sCD163,
KT ratio, and I-FABP were not significantly associated with
venular caliber. KT ratio was inversely related to CRAE; the
slope was 2.0 (95% CI ¼3.6, 0.4), P¼ 0.02. In the simple
linear regression of biomarkers, no other biomarkers were
related to CRAE.
In the multiple linear regression of retinal vascular caliber
including baseline characteristics and plasma biomarkers
(Table 4), AMD was associated with dilation of retinal arterioles
(mean difference 9.1 lm; 95% CI, 5.2, 12.9; P < 0.001) and
venules (mean difference 10.9 lm; 95% CI, 5.3, 16.6; P <
0.001). Black race was associated with retinal arteriolar dilation
(mean difference vs. white race 9.7 lm; 95% CI, 5.6, 13.8; P <
0.001 and mean difference vs. other race 1.7 lm; 95% CI3.1,
6.5) and retinal venular dilation (mean difference vs. white
race, 12.4 lm; 95% CI, 6.4, 18.4; P < 0.001 and mean
difference vs. other race, 6.5 lm; 95% CI 0.5, 13.5).
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Hyperlipidemia was associated with retinal venular narrowing
(mean difference, 7.5; 95% CI, 13.7, 1.2; P ¼ 0.02).
Cardiovascular disease was associated with retinal arteriolar
narrowing (mean difference¼5.2 lm; 95% CI10.3,0.1; P
¼ 0.05). Age was associated with arteriolar narrowing (slope¼
0.26 lm/year; 95% CI, 0.46, -0.06; P ¼ 0.009). Among the
inflammatory biomarkers, IL-6 was associated with venular
dilation (slope ¼ 5.3 lm/standard deviation log10[plasma IL-6
concentration]; 95% CI, 2.7, 8.0; P < 0.001).
As a sensitivity analysis, the multiple linear regression was
performed without AMD in the model. The results (Supple-
mental Table 1, available online) were similar in direction and
magnitude to those with AMD in the model with two
exceptions. Without AMD in the model, IL-6 plasma level
was associated with retinal arteriolar dilation (slope¼ 2.1 lm/
standard deviation log10[plasma concentration IL-6]; P¼ 0.03)
and cardiovascular disease was not associated with retinal
arteriolar narrowing.
The total effect of each biomarker on CRAE and CRVE was
tested across various subgroups including AMD status, age, sex,
and race. There was no evidence of a significant subgroup
interaction effect (P < 0.01) although the power to detect
these effects is limited (data not shown).
DISCUSSION
Our data suggest that multiple factors are associated with
retinal vascular caliber. Increasing age and cardiovascular
disease are associated with retinal arteriolar narrowing, and
hyperlipidemia is associated with retinal venular narrowing.
Black race is associated with both retinal arteriolar and venular
dilation. As previously reported,19 AMD is associated with both
retinal arteriolar and retinal venular dilation. The results for the
inflammatory biomarkers are more complex. In the simple
linear regression, retinal venular dilation was associated with
the inflammatory biomarkers CRP, IL-6, and IP-10. In the
multiple linear regression, retinal venular dilation was associ-
ated only with elevated plasma levels of IL-6. C-reactive protein
is an acute phase reactant, which is elevated in several
conditions characterized by systemic inflammation, including
infection and autoimmune or auto-inflammatory diseases. In
animal models, CRP has been reported to inhibit endothelial
nitric oxide synthase (eNOS),33 plausibly contributing to
endothelial dysfunction, atherosclerosis, and retinal vascular
caliber. Nevertheless, Mendelian randomization studies cast
doubt on a direct causal contribution of CRP to cardiovascular
disease in man.34 IL-6 is a proinflammatory cytokine, secreted
by several innate immune cells and B-cells, and it is an inducer
of CRP synthesis in the liver.29,30 The association of retinal
venous dilation with both CRP and IL-6 levels in the simple
linear regression strengthens the inference that retinal venous
dilation is related to systemic inflammation, since these
biomarkers are mechanistically linked in vivo. That the
association of retinal venular dilation remains associated with
IL-6 but not CRP in the multiple linear regression is consistent
with the role of IL-6 role as an inducer of CRP. IP-10 is a marker
of type I and type II interferon responses typically induced by
bacterial or viral infection, and its association with retinal
venous dilation suggests that HIV infection or infections with
co-pathogens may contribute to this inflammatory state.29,30
Elevations of CRP, IL-6, and IP-10 are associated with mortality
in persons with HIV infection and AIDS.29,30,35–40 Elevated IL-6
and CRP levels also predict increased atherosclerosis and an
increased risk of incident myocardial infarction in persons with
ART-treated HIV infection.41–44
Increasing levels of sCD14 and sCD163 are markers of
monocyte/macrophage activation, are associated with large-
vessel atherosclerosis and inflammation, and are associated
with an increased risk of mortality in HIV-infected per-
sons,30,35–38,42,45,46 but were not associated with retinal
vascular caliber in our study. These results suggest that
monocyte/macrophage activation may not contribute substan-
tially to retinal vascular changes in persons with AIDS.
Elevation of blood I-FABP level is associated with gut epithelial
death or turnover, is linked to microbial translocation, and is
associated with AIDS dementia and mortality.30,47
Elevated KT ratio is a measure of indoleamine 2,3
dioxygenase (IDO) upregulation, which is induced by interfer-
TABLE 1. Characteristics of the Study Population of Persons with AIDS
Characteristic Results (n ¼ 454)
Design variable
Age-related macular degeneration, n (%) 150 (33.0)
No age-related macular degeneration, n (%) 304 (67.0)
Demographics
Age (y), mean 6 SD 43.3 6 9.9
Sex, n (%)
Men 351 (77.3)
Women 103 (22.7)
Race, n (%)
White 180 (39.6)
Black 190 (41.8)
Other 84 (18.5)
Smoking history, n (%)
Never smoker 146 (38.9)
Former smoker 127 (33.9)
Current smoker 102 (27.2)
Comorbidity, n (%)
Hypertension 112 (24.7)
Diabetes 40 (8.8)
Hyperlipidemia 97 (21.4)
Cardiovascular disease 58 (15.4)
Renal disease (elevated serum creatinine) 26 (5.7)
HIV treatment, n (%)
On antiretroviral therapy at enrolment 390 (85.9)
Received antiretroviral therapy at or
before enrolment
423 (93.2)
Virology/Immunology
HIV load (log10(copies/mL))
Mean þ SD 3.2 6 1.4
Distribution, n (%)
<2.6 164 (38.8)
>2.6 to 3.0 76 (18.0)
>3.0 183 (43.3)
CD4þ T cells (cells/lL)
Median (25th, 75th percentile) 214 (93, 361)
Distribution, n (%)
<100 117 (25.9)
100–199 95 (21.0)
200–499 185 (40.9)
>500 55 (12.2)
Inflammatory biomarkers* (mean þSD)
CRP (log10[mg/L]) 0.3360.60
IL-6 (log10[pg/mL]) 0.3460.40
IP-10 (log10[pg/mL])) 2.3760.38
sCD14 (log10[lg/mL])) 0.4260.12
sCD163 (log10[ng/mL])) 2.8260.25
KT ratio (log10[ratio]) 1.7660.29
I-FABP (log10[pg/mL]) 3.1560.32
* CRP, C-reactive protein; IL-6, interleukin-6; IP-10, interferon-c
inducible protein-10; sCD14, soluble CD14; sCD163, soluble CD163;
KT ratio, kynurenine tryptophan ratio; I-FABP, intestinal fatty acid
binding protein.
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ons and other inflammatory mediators, and results in T cell
proliferative defects, loss of gut barrier integrity, and neuro-
toxicity.30 Elevations of the KT ratio are associated with
increased risks of atherosclerosis and mortality in both HIV-
infected and HIV-uninfected persons.30,48–50 Although not
associated with CRVE changes, KT ratio was associated with
retinal arteriolar narrowing in the simple linear regression, but
not the multiple linear regression. Retinal arteriolar narrowing
is associated with hypertension and aging in both HIV-infected
and HIV-uninfected persons.18–24
Caution should be taken in interpreting our results. LSOCA
enrolled participants with AIDS and not with earlier stages of
HIV infection, so its generalizability to the entire HIV epidemic
is uncertain. However, participants enrolled in LSOCA are
similar to those with AIDS in the United States,27 and as such
the results should be applicable to patients with AIDS. The data
set consisted of 150 participants with AMD matched to 2:1
with age-, sex-, and race/ethnicity-matched controls. The
multiple linear regression could only be performed on the
subset of participants with results for all 21 candidate variables,
resulting in a reduction in the available sample size by
approximately one-third. We did not evaluate HIV-uninfected
persons. Nevertheless, the inflammatory biomarkers in this
study were chosen because they represent immune and
TABLE 2. Demographics, Comorbidities, HIV Treatment, Virologic, and Immunologic Variables and Retinal Vascular Caliber in Persons With AIDS
Variable Number
Central Retinal Artery Equivalent Central Retinal Vein Equivalent
Mean, lm SD*, lm P Value Mean, lm SD, lm P Value
Design 0.001 <0.001
AMD 150 151 16 229 23
No AMD 304 146 17 220 24
Demographics
Age, y <0.001 0.07
<55 356 149 16 224 23
>55 98 141 17 219 27
Sex <0.001 0.05
Male 351 146 16 222 25
Female 103 153 16 227 21
Race <0.001 <0.001
Black 190 151 18 230 23
White 180 143 15 218 24
Other 84 148 15 221 22
Smoking history 0.15 0.001
Never 146 144 16 218 26
Former 127 148 16 229 23
Current 102 148 18 222 23
Missing 79 150 16 226 22
Comorbidity
Hypertension 0.01 0.26
Absent 342 149 17 224 24
Present 112 144 15 221 23
Diabetes 0.72 0.45
Absent 414 147 17 223 24
Present 40 147 17 226 24
Hyperlipidemia 0.12 0.008
Absent 357 148 17 224 24
Present 97 145 15 218 24
Cardiovascular disease 0.03 0.28
Absent 319 147 17 223 24
Present 58 142 16 219 24
Renal disease 0.09 0.38
Absent 428 148 17 224 24
Present 26 142 17 219 29
HIV treatment
Enrolment 0.05 0.005
On ART 390 147 17 222 25
Not on ART 64 151 16 231 19
ART at or prior to enrolment 0.29 0.10
Ever received 423 147 17 223 24
Never received 31 150 17 230 17
Virology/immunology
HIV load (log10(copies/mL)) 0.04 0.13
>2.6 260 149 16 225 23
<2.6 163 146 17 221 25
CD4þ T cells 0.71 0.79
<200 cells/lL 212 148 17 224 24
>200 cells/lL 240 147 16 223 24
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inflammatory pathways operative in both HIV-infected persons
and in HIV-uninfected elderly. The persistent inflammatory
state in ART-treated, immunorestored, HIV-infected persons
and its overlap with the phenomenon of immunosenescence in
HIV-uninfected older persons suggests that associations with
systemic inflammation may be easier to detect in populations
such as LSOCA than in the general population. The relevance
of LSOCA inferences to aging is strengthened by our results
demonstrating that participants in LSOCA have retinal vascular
calibers comparable to HIV-uninfected persons at least 10 years
older.18 Lastly, because only the systemic compartment
(plasma) could be sampled, we cannot ascertain the role, if
any, of locally-produced (i.e. intraocular) inflammatory medi-
ators on retinal vascular caliber. Nevertheless, these data
suggest a potential role for systemic inflammation in retinal
vascular caliber, which may be relevant to both HIV-infected
and HIV-uninfected persons.
In conclusion, our data demonstrate that retinal arteriolar
and venular dilation in patients with AIDS is associated with
AMD and with Black race. Age and cardiovascular disease are
associated with retinal arteriolar narrowing, and hyperlipid-
emia with retinal venular narrowing. Elevation of plasma levels
of the inflammatory biomarker IL-6, a marker of innate immune
system activation and systemic inflammation, is associated
TABLE 3. Simple Linear Regression of Retinal Vascular Caliber on Plasma Inflammatory Biomarkers in Persons With AIDS
Biomarker Number
Central Retinal Artery Equivalent Central Retinal Vein Equivalent
Slope* 95% CI P Value Slope* 95% CI P Value
CRP 400 1.3 0.3, 2.9 0.11 3.7 1.4, 6.0 0.002
IL-6 451 0.6 0.9, 2.1 0.44 3.7 1.6, 5.8 0.001
IP-10 448 0.5 1.0, 2.0 0.51 2.8 0.6, 5.0 0.01
sCD14 452 0.3 1.9, 1.3 0.70 0.8 1.6, 3.1 0.53
sCD163 454 0.6 2.2, 0.9 0.44 1.1 1.1, 3.3 0.32
KT ratio 429 2.0 3.6, 0.4 0.02 0.9 3.3, 1.5 0.45
I-FABP 450 0.6 2.1, 0.9 0.44 1.1 3.3, 1.2 0.34
* Slope in lm/standardized unit. Standardized unit: standard deviation log10(plasma biomarker level).
FIGURE 1. Linear regression of central retinal artery equivalent (CRAE) on (a) age, (b) CRP, (c) IL-6, (d) IP-10, (e) sCD14, (f) soluble CD163
(sCD163), (g) KT ratio, (h) I-FABP.
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with retinal venular dilation. The simple linear regression
suggested an association with CRP and IP-10, also markers of
innate immune system activation and systemic inflammation.
The multiple linear regression without AMD in the model
suggested a possible association of plasma IL-6 with retinal
arteriolar dilation as well. Collectively, these results underscore
a link between chronic inflammation and vascular disease in
ART-treated HIV-infected persons,41,42,46,50 and the common
features of accentuated aging in HIV-infected persons and
immunosenescence in the HIV-uninfected elderly suggest a
similar relationship may be present in HIV-uninfected persons
as well.
FIGURE 2. Linear regression of CRVE on (a) age, (b) CRP, (c) IL-6, (d) IP-10, (e) sCD14, (f) sCD163, (g) KT ratio; (h) I-FABP.
TABLE 4. Multiple Linear Regression* of Retinal Vascular Caliber in Persons with AIDS
Categorical Variables
Central Retinal Artery Equivalent Central Retinal Vein Equivalent
Mean D 95% CI P Value Mean D† 95% CI P Value
AMD (yes vs. no) 9.1 5.2, 12.9 <0.001 10.9 5.3, 16.6 <0.001
Race <0.001 <0.001
Black vs. white 9.7 5.6, 13.8 12.4 6.4, 18.4
Black vs. other 1.7 3.1, 6.5 6.5 0.5, 13.5
Sex, male vs. female 3.6 8.2, 0.9 0.12 0.8 7.2, 5.7 0.82
Hyperlipidemia 7.5 13.7, 1.2 0.02
Cardiovascular disease 5.2 10.3, 0.1 0.05
Continuous Variables Slope 95% CI P Value Slope 95% CI P Value
Age, y 0.26 0.46, 0.06 0.009 0.25 0.53, 0.03 0.08
IL-6, standardized unit‡ 5.3 2.7, 8.0 <0.001
* Based on forward selection with P¼ 0.05 for entry using 18 candidate variables and forcing age, race, and sex into the model (see text) among
297 participants with complete data.
† Mean D¼ mean difference for categorical variables. Slope¼ slope of the regression line for continuous variables.
‡ Standardized unit ¼ standard deviation log10(plasma biomarker level).
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